Princeton-based Certara, a drug development and regulatory sciences company, announced that it has acquired BaseCase Management GmbH, a life sciences data visualization company headquartered in Berlin.
BaseCase will join Certara’s Strategic Consulting Services division.
“We are delighted that BaseCase is joining Certara, and we are looking forward to expanding the applications for its user-friendly, mobile communications technology. BaseCase simplifies communication of complex data and models,” said Thomas Kerbusch, president of Certara Strategic Consulting Services. “BaseCase’s interactive platform will enable pharmaceutical and medical technology companies to visualize model results and large, real-world datasets to make sound decisions quickly, within controlled communication cascades.”
BaseCase technology will allow users to create content, including embedded data visualization assets such as spreadsheets, calculators, communication tools and videos in a web browser.
“The BaseCase team is excited to join Certara and take adoption of our visualization and communications platform to the next level. We are confident that we are a great match. Both companies have comparable cultures — entrepreneurial, dynamic, diverse and quality driven — and possess a similar mix of scientific and software engineering staff. With the growing acceptance of modeling and simulation in life sciences comes the need to simplify complex data science concepts and results. Certara is the perfect home for BaseCase,” said BaseCase CEO Gijs Hubben.
Financial terms were not disclosed.
“Certara’s extensive software development capability and deep expertise in model-informed drug development will enable us to further accelerate BaseCase’s evolution and growth in this expanding market space,” said Diarmuid Glynn, chief technology officer at BaseCase. “We have already identified several expansion projects that will result from the merger.”
